are the synthesis and some aspects of the pharmacology of acetylseco hemicholinium-3 (acetylseco HC-3), the acetylated open ring analogue of hemicholinium-3 (HC-3). The effects of both compounds were determined in uiuo on rat brain acetylcholine (ACh), 'Y-choline (14C-Ch) incorporation into 14C-acetylcholine (14C-ACh) and on one way jump box avoidance and escape behavior in naive and trained rats. In addition, the in vitro effects of both drugs were determined on choline acetyltransferase activity (ChAc) in rat brain.
. Comparison of structures of acetyiseco HC-3 and HC!-3. Note that both compounds are bisquaternary nitrogen derivatives. HC-3 exists as the hemiacetyl ring structure.
1959) and that acetylseco l-K-3, the acetate derivative of the opened ring form of He-3 cannot exist in the hem&eta1 form suggests that acetylseco HC-3 might possess different pharmacological actions. MAGGIO and HAARSTAD (unpublished observations) have reported critical pharmacological differences between HC-3 and acetylseco HC-3 in which inhibition ofcholine acetyltransferase (a&y1 CoA-choline 0-acetyltransferase EC2.3.1 Xi, ChAc) by the latter is especially prominent (DE B&BIAN VERSIXR, HAARSTAD and WHITE, 1968, 1969) . The present manuscript describes further some of the pharmacological properties of acetylseco HG3 which indicate it to be an important new tool to inhibit ACh synthesis in the brain when the drug is given intraventricularly.
METHODS
The compound, u,cw-dibromo-4,4'-biacetophenone, which is a precursor for acetylseco HC-3, was prepared according to the method of HAARSTAI) and SCHUE~ER (unpublished observations) which is a modification of the method of LONG and SCHUELER (1954) . Acetylseco HC-3 dibromide, [4,4'-diphenylylenebis (2-oxoethylene)] bis [(Zacetoxyethyl) dimethylammonium bromide], was prepared as follows: 0.5 g of ff,u-dibrom~,~-bia~tophenone was dissolved in SO ml of boiling tetrahydrofuran. The solution was allowed to cool to about 50°C. Two ml of freshly distilled 2-dimethylaminoethyl acetate was added all at once while the solution was being swirled. A white precipitate began to form almost immediately. The mixture was allowed to stand at room temperature for 7 hr. The mixture was filtered through a sintered glass funnel. The precipitate was washed well with tetrahydrofuran, then diethyl ether and dried in a vacuum desiccator over anhydrous calcium chloride. Yield O-7 g (85%) (m.p., becomes an amber glass at 195", begins to blacken at 205°C. (uncorr.); ImaX 305 nm, log Qn, 4.52; acetate carbonyl, 5.73 pm (s) ketone carbonyl, 5.91 ,um (s). Anal. Calcd for CzsH,,BrzNz02: C, 51.08% ; H, 5.82% ; N, 4.25%. Found C, 50.91% ; H, 5.60; N, 3.99%.
It should be noted that acetylseco HC-3 is prepared analytically pure without the use of a recrystallization step. This has been demonstrated by analyses of several separate preparations. This is to obviate the possibility of transesterification which would lead to the formation of HC-3 itself.
Animal preparations
Male Holtzman rats in groups of 6-12 were used throughout. Both young rats (20-30 days old) as well as adults (90 days and older) were used with intraventricular injection of HC-3 and acetylseco HC-3 in various experiments involving steady state, ACh depletion and 14C-choline (14C-Ch) incorporation into "C-acetylcholine (14C-ACh). All drug doses were calculated as base. Control solutions of equimolar amounts of NaBr were also used. The young rats were anaesthetized with diethyl ether-air and the bregma exposed to use as a reference point. A puncture point was made on one side approximately 13 mm posterior and 13 mm lateral from the bregma to inject either HC-3 or acetylseco HC-3 in the area of the lateral ventricle. A microliter syringe and a needle with a stop were used to inject to a depth of 4-4.5 mm. Rats usually recovered 3-4 min later from anaesthesia and were killed 3 hr later by guillotine. Brains were removed within 45 set for various assays. Male Holtzman rats 90 days and older were implanted with polyethylene cannulae as described by ROBINSON, HENGEVELD and DE BALBIAN VERSTER (1969) and ALTAFFER, DE BALBION VERSTER, HALL, LONG and D'ENCARNACAO (1970) under pentobarbital anaesthesia. Animals were used 7-14 days after cannulation similar to the young rats except that no anaesthetic was involved on the day of the experiment. Sacrifice occurred 10 min after intraventricular injection of 14C-Ch.
Acetylcholine assay
After sacrifice by decapitation brains were removed, homogenized and ACh extracted by the acidic alcohol method described by STONE (1955) and CROSSLAND (1961) . Extracts were bioassayed on the frog rectus abdominus muscle as per DREN and DOMINO (1968) . As suggested by FELDBERG (1945) , ACh standards were prepared in alkali-inactivated extracts to control for the presence of sensitizing factors in the brain tissue. Although acetone (85x)-1N formic acid (15%) has been reported to be a superior extraction procedure (TORU and APRISON, 1966) , it was not used in the bioassay experiments reported because in our hands the frog rectus muscle responded less reproducibly. This extraction procedure was used, however, for the radiochemical studies described below.
Choline acetyltransferase assay
Adult rat brains were used as a source of choline acetyltransferase (ChAc). On the day of the experiment, a rat was decapitated, the brain quickly removed, weighed, and a 10% homogenate prepared with distilled water. The ChAc assay procedure was a modification by DE BALBIAN VERSTER of the method of SCHRIER and SCHUSTER (1967) and MCCAMAN and HUNT (1965) . The final concentration of the buffer substrate was: O-3 M sodium chloride, 0.01 M choline chloride, 2 x lo-4~ physostigmine, 0.02 M magnesium sulphate, 0.05% bovine plasma albumin, 0.08~ potassium phosphate (pH 7.4) and 6.2 x 10m4~ acetyl CoA. 1 4C-Acetyl CoA was mixed with cold acetyl CoA to yield approximately 20,000 dis/min per incubation tube. Ten ~1 of the 10% homogenate (1 mg tissue equivalent) were pipetted into each incubation tube. One hundred ,~l of the substrate were then added with an automatic pipetter. The tubes were incubated for 30 min at 37°C after which the reactions were terminated by placing the tubes in a boiling water bath for about 5 min. The reaction mixture was then placed onto 0.5 x 80 cm columns (diSPo pipets) prepared from prewashed Dowex 1 x 8 .chloride. The incubation tubes were then washed with 3 consecutive 0.5 ml water washes, each wash being applied to the Dowex column. The effluent was collected directly into scintillation vials, 15 ml of dioxane scintillation fluid (8.0 g PPO, 0.1 g POPOP, 110 g naphthalene, 1 1 dioxane) was added to each vial and the samples counted in a Beckman ambient temperature scintillation counter.
Incorporation of "C-choline into "C-acetylcholine
Unanaesthetized adult male Holtzman rats cannulated at least one week previously were used. Drug and control rats were always done together. Ten min after injection of 20 1.11 1 4C-Ch (1 $i ; 61 mCi/mm) alone or simultaneously with acetylseco HC-3 (20 pg base), the rat was decapitated, the brain quickly removed, weighed, and homogenized in acetone: IN formic acid (85 : 15). The extraction method of TORU and APRISON (1965) as adapted by SAELENS, ALLEN and SIMKE (1970) was used. After the separation of the organic and HZ0 extracts, paper electrophoresis as described by POTTER and MURPHY (1967) and SAELENS et al. (1970) was used to separate Ch and ACh in the H,O extract. The areas were visualized in iodine vapor and the appropriate sections placed into scintillation vials. One ml H,O and 10 ml of the above described dioxane solution were added to each vial. Counting was done in an ambient temperature Beckman scintillation counter.
One way avoidance behavior
The effects of intraventricular acetylseco HC-3, HC-3, and different equimolar amounts of NaBr for the two compounds were studied on acquisition and retention of rat one way avoidance behavior. The apparatus used was an adaptation of that used by CALDWELL, OBERLEAS, CLANCY and PRAASAD (1970) as described by TENEN (1966) . The behavioral parameters were as follows: The conditioned stimulus (CS) was a 5 set presentation of four 7.5 W red lights with the simultaneous presentation of an escape ledge. At the end of 5 set, the CS overlapped with a 5 set unconditioned stimulus (US) that consisted of 1 mA 60 Hz electric shock delivered to the grid floor. When the rat jumped on the ledge, the sequence was terminated. A 30 set ledge rest period then ensued. If at the end of this time the animal still persisted in sitting on the ledge, it was automatically pushed off by an electromechanical moving wall. Random intertrial intervals were maintained with a mean of 30 set and a range of 15-60 sec. After intraventricular injection, a 10 min period was allowed before animals were given 50 trials. The entire session lasted about 1 hr. Naive animals were given a total of 50 acquisition trials under the drug and discarded. Trained animals were given 50 trials per day for 5 consecutive days to achieve a 90% avoidance criterion and then used for the drug studies.
RESULTS

Comparative effects of acetylseco HC-3 and HC-3 on brain acetylcholine
In view of the fact that quaternary nitrogen derivatives do not readily penetrate the bloodbrain barrier, both HC-3 and acetylseco HC-3 were given intraventricularly to young rats + hr prior to sacrifice. In Figure 2 the dose-effect relationships and per cent mortality are shown for groups of 6-10 rats per dose. Acetylseco HC-3 had a wider separation between pg of compound On the x axis is plotted the dose as base of the compound listed given intraventricularly. At 0 dose an equimolar amount of sodium bromide to 20 pg hemicholinium bromide was given. The mean f SE. for 6-12 rats is shown. Increasing doses of intraventricular acetylseco HC-3 (A-SECO) and HC-3 reduce total brain ACh and increase mortality. Note that acetylseco HC-3 is more potent in reducing brain ACh and is less toxic. All animals were killed & hr after drug administration.
the dose that lowers ACh in brain and lethality than HC-3. Furthermore, it was much more effective in reducing ACh at lower doses than HC-3. HC-3 appeared to be a more toxic compound than acetylseco HC-3. With either compound in doses of 50 pg intraventricularly there was a 50% mortality. Animals that received HC-3 exhibited shaking, twitching, rigid posture, sometimes convulsions and respiratory arrest. These effects were especially obvious with larger doses. After acetylseco HC-3 rats did not exhibit any of the characteristic behavior induced by HC-3. In general, they were not very responsive to handling. Both drugs caused over a 50% loss of ACh with larger doses. After about 1 pg of acetylseco HC-3 and 20 pg HC-3, no further drop in ACh was produced in rats that survived up to 3 hr after injection.
Time course of brain acetylcholine depletion following acetylseco HC-3 and He-3
In young rats intraventricular acetylseco HC-3 and HC-3 in doses of 20 pg total produced similar rates of brain ACh depletion which was maximal 30-60 min after injection. Groups of 8-10 rats were injected and sacrificed at 5, 15, 30 and 60 min later. The effects of acetylseco HC-3 appeared to be somewhat more rapid in onset in lower doses intraventricularly but both drugs showed similar levels of depletion of brain ACh at 60 min.
Acetylseco HC-3 inhibition of choline acetyltransferase activity in vitro Rat brain ChAc activity was determined in oitro at different concentrations of acetylseco HC-3 and HC-3 varying from lo-7 to IO-' M. Choline was present at lo-' M and acetyl CoA at 6.4 x 10m4 M. The results of one experiment are shown in Figure 3 , plotted as percent of control ChAc activity. HC-3 had no effect on ChAc activity. In contrast, acetylseco HC-3 was an inhibitor with an ISo of 1 x lo-5 M under these substrate concentrations. When this experiment was repeated with different batches of acetylseco HC-3 and acetyl CoA, the I,, values varied from 5 x 10 -6 M to 1 x lo-' M. The fact that several batches of of rat brain homogenate. On the x axis is given the molar concentration of the 2 compounds and on they axis the per cent of control ChAc activity. The mean *LE. of 4 separate determinations at each point is given. The substrate concentration for choline was 1 x 10m2 M and for acetyl CoA 6.4 x 10e4 M. Note that acetylseco HC-3 is an effective ChAc inhibitor with an I 5o of 5 x 10e6 M at these substrate concentrations.
acetylseco HC-3 showed similar chemical analyses and caused similar in u&o decreases in brain ACh when given intraventricularly suggests that the change in I,, values is due to different batches of commercial acetyl CoA. This problem has been observed by others using commercial acetyl CoA preparations containing impurities (FONNUM, 1969; SCHUBERTH, 1971) . Nevertheless, the results of the present experiments are clear in that acetylseco HC-3 is an inhibitor of ChAc activity but HC-3 is not. The mode of inhibition of ChAc by acetylseco HC-3 seems complex. DEBALBIAN VERSTER et al. (1968) found that it was competitive with acetyl CoA and non-competitive with choline. Our own data with crude brain enzyme preparations and unpurified commercial acetyl CoA suggests it is mixed. In Figures 4 and 5 are the summarized data of individual experiments in which the reciprocal of varying concentrations of acetyl CoA and Ch are plotted against the reciprocal of enzyme activity. These particular Lineweaver-Burk plots were determined using 1 x lo-5 M acetylseco HC-3. Statistical estimates of the K, and I&, were obtained using the computer analysis of WILKINSON (1961) . In Figure 4 acetyl CoA concentrations varied from 3-1 x lo-' M to 3.1 x lo-5 M. Choline concentration was lo-' M. All other substrates in the incubation mixture were as described in the Methods. A V,,, for acetyl CoA of 0.28 &-0.01 pmol/g per min was obtained without acetylseco HC-3 and 0.19 + 0.02 ,umol/g per min after the inhibitor. The K, without acetylseco WC-3 was 5.1 + 0.65 x 10V4 M and 1.4 f 0.34 x lo-3 M with 1 x lo-5 M acetylseco HC-3. These values depict a change caused by the presence of acetylseco HC-3 for both the V,,, and the K,,, of acetyl CoA. The results of an earlier experiment using different batches of drug and substrates also showed changes from normal in both V,,, and K,,, (see Table 1 ). The inhibition suggested by the use of a crude enzyme preparation and unpurified commercial acetyl CoA in the presence of acetylseco HC-3 is neither clearly competitive nor non-com~titive but might be classified as mixed (WEBB, 1963). Note that a competitive inhibition is observed. The K,,, and V,,,.. are given using the statistical estimate techniques of WILKINSDN (1961) for a range of 1 x 10V5 M. A smaller range is shown for the individual experiment whose data is plotted in this graph. Lineweaver-Burk analysis of data obtained by varying Ch from lo-' to lo-5 M is shown in Figure 5 . Acetyl CoA was held constant at 6.4 x 10m4 M. A Vm,, for Ch of 0.23 + 0.01 pmol/g per min without acetylseco HC-3 and 0.21 + 0.02 pmol/g per min with acetylseco HC-3 was obtained. The K,,, without acetylseco HC-3 was 1.3 + 0.11 x IO-3 M and 6.9 f 1.9 x 10e3 M with this inhibitor. It would appear that in this particular experiment, and at the molar ranges depicted, competitive inhibition is involved. Several other experiments performed over a period of one year with different batches of acetyl CoA and acetylseco HC-3 produced similar results, as shown in Table 1 .
Effect of intraventricular acetylseco HC-3 and HC-3 on "C-choline incorporation into "C-acetylcholine in vivo
As described in the Methods, 14C-Ch in a dose of 160 nmol and 1 &i was given intraventricularly to unanaesthetized adult rats with indwelling polyethylene brain cannulae. A time interval of 10 min between injection and decapitation was chosen to minimize the effects of counting recycled r4C-Ch and because our previous experiments indicated incorporation of at least 5% i4C-Ch into 14C-ACh at this time. The effects of acetylseco HC-3 and HC-3 on in vivo incorporation of 14C-Ch into i4C-ACh are shown in Figure 6 . The values of at least 6 animals per drug are normalized as per cent change from control. Acetylseco HC-3 drastically reduced i4C-Ch incorporation into r4C-ACh to 15.5 + 1.1% of control. HC-3 in equal amounts (20 p(g) reduced 14C-Ch incorporation to 48.0 f9.6%. The mean f S.E. extractable free pool of r4C-Ch was 157.5 + 15.5% after acetylseco HC-3 and only 118.4 + 5.7% after HC-3. These differences areboth statistically significant (P < 0.001 for acetylseco HC-3 and P < 0.05 for HC-3).
Comparative effects of acetylseco He-3 and He-3 on rat one way jump box avoidance and escape behavior Groups of 8-l 2 rats were studied on acquisition and performance in a jump box following intraventricular equimolar NaBr and 20 pg intraventricular acetylseco HC-3 and HC-3. Both of these compounds reduced brain ACh to about 50% of control within 3 hr. Ten minutes after intraventricular injection rats were given 50 trials which lasted about 1 hr. Both naive and trained (90% avoidance criterion) animals were run. The data obtained are given in a bar graph format as mean per cent of total response + S.E. for each series in Figure 7. Both acetylseco HC-3 (P < O-01) and HC-3 (P < 0.001) significantly reduced acquisition and increased escape responding of naive as well as trained animals. Naive animals were more affected than trained animals. HC-3 produced more behavioral toxicity than acetylseco HC-3 even though both drugs reduced total brain ACh to similar levels. Gross behavioral alterations such as tremors were also more obvious following HC-3,
DISCUSSION
Several classes of ChAc inhibitors are now known. All have some disadvantages as neuropharmacological tools. Sulphhydryl inhibitors such as iodoacetate and p-chloromercurib-enzoate are relatively nonspecific (RELSBERG, 1957; MANNERVIK and SORBO, 1970) . Cysteine is also a ChAc inhibitor but in excessive concentrations (MORRIS, HEBB and BULL, 1966) . Several halogen derivatives of ACh are known to be uncompetitive inhibitors of ChAc in concentrations of 6 x IO-' M (PERSSON, LAIRSON, SCHUBERTH and Sonno, 1967; MORRIS and GREWAAL, 1969; HENDERSON and RAMA SASTRY, 1972) . Perhaps the best known inhibitors of this enzyme are the styryIpyridine analogues (ALLEN, CARLSON and CAVALLITO, 1970; CAVALLITO et at., 1969 CAVALLITO et at., , 1970a SMITH, CAVALLIT~ and FOLDES, 1967; WHITE and CAVALLITO, 1970) . To this Iist of ChAc inhibitors one can add acetylseco HC-3. The compound is clearly different from HC-3, although it does share other pharmacolo~~l actions The data from naive animals is to the left and trained animals to the right. Note that both agents depressed acquisition of avoidance more than escape behavior in both naive and well trained animals but that HC-3 is more potent. All the animals were run 10 min after intraventricular injection for a total of 50 trials which lasted approximately 1 hr. Note that both drugs affected naive more than trained animals. Each bar graph represents the mean f SE. of 8-12 animals. A group comparison f-test of control and drug treated groups was done. Significant differences of P for avoidance behavior are shown as ** < 0.01 and *** < 0401.
of HC-3, including reduced toxicity after Ch (MAGGIO, 1968; MAGGIO and HAARSTAD, unpublished observations). The fact that acetylseco HC-3 is a bischoline ester makes it susceptible to hydrolysis, although strangely it has not been reported to be a substrate for cholinesterase in vitro.
Studies of the action of intraventricular HC-3 and acetylseco HC-3 on total rat brain ACh indicate that both reduce ACh, although with different doses, times and lethality. Because of these differences, a study of the in vitro effects of these compounds on rat brain ChAc was deemed important. HC-3 was shown to have no effect while acetylseco HC-3 was found to be a potent inhibitor (Fig. 3) , an indication that the two compounds were both reducing brain ACh through different mechanisms. This does not rule out, however, the possibility that acetylseco HC-3 also affects the transport of Ch in a manner similar to HC-3. Like HC-3, acetylseco HC-3 is found to markedly alter normal liver metabolism producing fatty liver (MAGGIO and HAARSTAD, unpublished observations). The fact that Ch reverses many of the pharmacological actions of acetylseco HC-3 is further suggestion of an action on Ch transport.
Kinetic studies using Lineweaver-Burk analysis do indicate that acetylseco HC-3 is a competitive inhibitor of Ch. Acetylseco HC-3 also has many similarities with ACh. MAGGIO and HAARSTAD (unpublished ob~rvations) found acetylseco HC-3 to be a potent parasympathom~etic additive with ACh. HC-3 did not exhibit these properties. Ileum contractions elicited by acetylseco HC-3 were blocked by atropine but not hexamethonium. Studies of base-catalyzed hydrolysis indicate that the ACh moiety of acetylseco HC-3 is similar in chemical reactivity to ACh. If acetylseco HC-3 has similarities to ACh, it could be acting like ACh through substrate inhibition of ChAc. KAITA and GOLDBERG (1969) have shown that increasing amounts of ACh produce competitive inhibition with Ch. If acetylseco HC-3 is occupying the choline site on the enzyme (as ACh would), there would be no acetylation of Ch. There would be no competition for the enzyme site normally occupied by acetyl CoA. Our enzyme kinetics, however, indicate a mixed type of interaction with acetyl CoA. It might be that the greater size of the acetylseco IX-3 molecule is creating a physical hindrance to the attachment of acetyl CoA to the enzyme site.
Of special importance are further studies using purified ChAc to better define the kinetics of inhibition by acetylseco HC-3. The studies reported in this paper should be regarded as preliminary in view of the use of commercially available 14C-acetyl CoA and rat brain homogenate as the enzyme source. In spite of these shortcomings, the data indicate that acetylseco HC-3 may become an important neuropharmacological tool. Results of intraventricular injections of acetylseco HC-3 or HC-3 simultaneously with pulse doses of 14C-Ch further indicate that acetylseco HC-3 has a more potent effect than HC-3 on incorporation of Ch into ACh. Again, this does not eliminate the possibility that acetylseco HC-3 affects Ch transport as well as inhibition of ChAc. Its greater potency than HC-3 for reduction of ACh could be due to the combined effects of the two actions. DIAMOND and KENNEDY (1969) have shown that HC-3 inhibits incorporation of choline into phosphorylcholine. The possibility that acetylseco HC-3 may also do the same must also be studied.
The behavioral effects of intraventricular acetylseco HC-3 as well as HC-3 indicate that these agents are useful in altering brain function in animals. Unexpectedly HC-3 produced greater behavioral toxicity than acetylseco HC-3. Furthermore, tremors were also more obvious after WC-3, suggesting it has further differences in action from acetylseco HC-3.
Of special interest is the fact that 4-( I-naphthylvinyl) pyridine hydrochloride (NVP), one of the potent styrylpyridine derivatives of CAVALLITO et al. (1969, 1970a, b) , had negligible behavioral effects in rats unless massive doses were given i.p. (GOLDBERG, SLEDGE, ROBI-CHAND and DUBINSKY, 1972) . Of course, this may have been because NVP does not readily penetrate the blood-brain barrier. In the present study acetylseco HC-3 was given intraventricularly to avoid its obvious peripheral effects when given parenterally. Further studies comparing intraventricular NVP and acetylseco HC-3 on various animal behaviors and possible antagonism by Ch would be of considerable interest.
